Skip to main content

. 1991 Jan;63(1):134–135. doi: 10.1038/bjc.1991.27

In vivo uptake of 131I-5-iodo-2-deoxyuridine by malignant tumours in man.

P A Philip ¹, K D Bagshawe ¹, F Searle ¹, A J Green ¹, R H Begent ¹, E S Newlands ¹, G J Rustin ¹, T Adam ¹

PMCID: PMC1971655 PMID: 1989652

134

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Bagshawe K. D., Boden J., Boxer G. M., Britton D. W., Green A., Partridge T., Pedley B., Sharma S., Southall P. A cytotoxic DNA precursor is taken up selectively by human cancer xenografts. Br J Cancer. 1987 Mar;55(3):299–302. doi: 10.1038/bjc.1987.58. [DOI] [PMC free article] [PubMed] [Google Scholar]
Bagshawe K. D. Reversed-role chemotherapy for resistant cancer. Lancet. 1986 Oct 4;2(8510):778–781. doi: 10.1016/s0140-6736(86)90301-6. [DOI] [PubMed] [Google Scholar]
Brammer I., Zywietz F., Jung H. Changes of histological and proliferative indices in the Walker carcinoma with tumour size and distance from blood vessel. Eur J Cancer. 1979 Nov;15(11):1329–1336. doi: 10.1016/0014-2964(79)90109-9. [DOI] [PubMed] [Google Scholar]
Curt G. A., Clendeninn N. J., Chabner B. A. Drug resistance in cancer. Cancer Treat Rep. 1984 Jan;68(1):87–99. [PubMed] [Google Scholar]
Goldie J. H., Coldman A. J. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res. 1984 Sep;44(9):3643–3653. [PubMed] [Google Scholar]
Kinsella T. J., Russo A., Mitchell J. B., Collins J. M., Rowland J., Wright D., Glatstein E. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer. Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1941–1946. doi: 10.1016/0360-3016(85)90275-5. [DOI] [PubMed] [Google Scholar]
PRUSOFF W. H. A REVIEW OF SOME ASPECTS OF 5-IODODEOXYURIDINE AND AZAURIDINE. Cancer Res. 1963 Sep;23:1246–1259. [PubMed] [Google Scholar]
PRUSOFF W. H. Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim Biophys Acta. 1959 Mar;32(1):295–296. doi: 10.1016/0006-3002(59)90597-9. [DOI] [PubMed] [Google Scholar]
Sneider T. W., Potter V. R. Alternative de novo and "salvage" pathways to thymidine triphosphate synthesis: possible implications for cancer chemotherapy. Cancer Res. 1969 Dec;29(12):2398–2403. [PubMed] [Google Scholar]
Tattersall M. H., Harrap K. R. Changes in the deoxyribonucleoside triphosphate pools of mouse 5178Y lymphoma cells following exposure to methotrexate or 5-fluorouracil. Cancer Res. 1973 Dec;33(12):3086–3090. [PubMed] [Google Scholar]
Tubiana M., Frindel E., Vassort F. Critical survey of experimental data on in vivo synchronization by hydroxyurea. Recent Results Cancer Res. 1975;(52):187–205. doi: 10.1007/978-3-642-80940-8_22. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES